Boron ameliorates fulminant hepatic failure by counteracting the changes associated with the oxidative stress.
Boron has well-defined biological effects and may be of therapeutic benefit. In the current paper, the effect of boron in the form of borax was tested in experimental animal model of fulminant hepatic failure (FHF). The syndrome was induced in female Wistar rats by three consecutive daily intraperitoneal injections of thioacetamide (400 mg/kg). In the treatment groups, rats received borax (4.0 mg/kg) orally for three consecutive days followed by thioacetamide. The group administered with thioacetamide plus vehicle, and the borax alone treated rats served as controls. In all groups, rats were terminated 4 h after administering the last dose of thioacetamide, and the tissue/serum was used to measure hepatic levels of thiobarbituric acid reactive substances, reduced glutathione, and various enzymes associated with oxidative stress including peroxide metabolizing enzymes and xanthine oxidase. In thioacetamide treated group, many fold increase in the activity level of serum marker enzymes suggesting FHF was observed that could be brought down significantly in rats receiving boron. Modulation and a correlation in the activity level of oxidant generating enzyme and lipid peroxidation as well as hepatic glutathione level was also observed in rats receiving thioacetamide. In the group receiving boron followed by thioacetamide, these changes could be minimized moderately. The activity level of the peroxide metabolizing enzymes and the tripeptide glutathione, which decreased following thioacetamide treatment were moderately elevated in the group receiving boron followed by thioacetamide. The data clearly shows that borax partly normalizes the liver and offsets the deleterious effects observed in FHF by modulating the oxidative stress parameters.
Pawa
Sonica
S
Department of Biochemistry, Faculty of Science, Jamia Hamdard, Hamdard University, Hamdard Nagar, New Delhi 1100 62, India.
Ali
Shakir
S
D000818:Animals; D001881:Borates / Q000627:therapeutic use*; D001895:Boron / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004798:Enzymes / Q000378:metabolism; D005260:Female; D005978:Glutathione / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D017114:Liver Failure, Acute / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008111:Liver Function Tests; D008315:Malondialdehyde / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism; D013853:Thioacetamide / Q000633:toxicity; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis
D001881:Borates; D004798:Enzymes; D017382:Reactive Oxygen Species; D017392:Thiobarbituric Acid Reactive Substances; D013853:Thioacetamide; C018851:borax; D008315:Malondialdehyde; D005978:Glutathione; D001895:Boron